CR Pharma completes RMB 1.00 billion first-tranche medium-term note issue at 1.53% coupon

Bulletin Express

07/22

China Resources Pharmaceutical Group Limited (abbreviated as CR Pharma) announced that its wholly owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, has finalised the issuance of the first tranche of its 2026 medium-term notes in mainland China.

The offering, completed on 21 July 2026, raised RMB 1.00 billion through three-year notes carrying an annual coupon of 1.53%. According to the filing, proceeds will be allocated to replenish working capital, repay interest-bearing debt and for other uses permitted under applicable laws and regulations.

The transaction is classified as inside information under Hong Kong Listing Rule 13.09 and Part XIVA of the Securities and Futures Ordinance. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.

The board is chaired by Mr Bai Xiaosong, with a total of 12 directors comprising executive, non-executive and independent non-executive members. All information above is drawn directly from the company’s disclosure dated 22 July 2026.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1111875986"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1111875986\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1111875986?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-22 18:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111875986","market":"us","top_or_hot":-1,"title":"CR Pharma completes RMB 1.00 billion first-tranche medium-term note issue at 1.53% coupon","media":"Bulletin Express","content":"<p>China Resources Pharmaceutical Group Limited (abbreviated as CR Pharma) announced that its wholly owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, has finalised the issuance of the first tranche of its 2026 medium-term notes in mainland China.</p>\n<p>The offering, completed on 21 July 2026, raised RMB 1.00 billion through three-year notes carrying an annual coupon of 1.53%. According to the filing, proceeds will be allocated to replenish working capital, repay interest-bearing debt and for other uses permitted under applicable laws and regulations.</p>\n<p>The transaction is classified as inside information under Hong Kong Listing Rule 13.09 and Part XIVA of the Securities and Futures Ordinance. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.</p>\n<p>The board is chaired by Mr Bai Xiaosong, with a total of 12 directors comprising executive, non-executive and independent non-executive members. All information above is drawn directly from the company’s disclosure dated 22 July 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CR Pharma completes RMB 1.00 billion first-tranche medium-term note issue at 1.53% coupon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCR Pharma completes RMB 1.00 billion first-tranche medium-term note issue at 1.53% coupon\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-07-22 18:20</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>China Resources Pharmaceutical Group Limited (abbreviated as CR Pharma) announced that its wholly owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, has finalised the issuance of the first tranche of its 2026 medium-term notes in mainland China.</p>\n<p>The offering, completed on 21 July 2026, raised RMB 1.00 billion through three-year notes carrying an annual coupon of 1.53%. According to the filing, proceeds will be allocated to replenish working capital, repay interest-bearing debt and for other uses permitted under applicable laws and regulations.</p>\n<p>The transaction is classified as inside information under Hong Kong Listing Rule 13.09 and Part XIVA of the Securities and Futures Ordinance. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.</p>\n<p>The board is chaired by Mr Bai Xiaosong, with a total of 12 directors comprising executive, non-executive and independent non-executive members. All information above is drawn directly from the company’s disclosure dated 22 July 2026.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03320","symbol_name":"華潤醫藥","start_time":0,"source_url":"","article_id":"1111875986","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111875986","pubTimestamp":1784715639,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"China Resources Pharmaceutical Group Limited (abbreviated as CR Pharma) announced that its wholly owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, has finalised the issuance...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03320":"华润医药"},"translate_title":"华润医药以1.53%票面完成首批10亿元中期票据发行","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1},"content_text":"China Resources Pharmaceutical Group Limited (abbreviated as CR Pharma) announced that its wholly owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, has finalised the issuance of the first tranche of its 2026 medium-term notes in mainland China.\nThe offering, completed on 21 July 2026, raised RMB 1.00 billion through three-year notes carrying an annual coupon of 1.53%. According to the filing, proceeds will be allocated to replenish working capital, repay interest-bearing debt and for other uses permitted under applicable laws and regulations.\nThe transaction is classified as inside information under Hong Kong Listing Rule 13.09 and Part XIVA of the Securities and Futures Ordinance. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.\nThe board is chaired by Mr Bai Xiaosong, with a total of 12 directors comprising executive, non-executive and independent non-executive members. All information above is drawn directly from the company’s disclosure dated 22 July 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}